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Abstract
Introduction: Several observational studies suggest that statins modulate the pathophysiology of sepsis and may
prevent its progression. The aim of this study was to determine if the acute administration of atorvastatin reduces
sepsis progression in statin naïve patients hospitalized with sepsis.
Methods: A single centre phase II randomized double-blind placebo-controlled trial. Patients with sepsis were
randomized to atorvastatin 40 mg daily or placebo for the duration of their hospital stay up to a maximum of
28-days. The primary end-point was the rate of sepsis progressing to severe sepsis during hospitalization.
Results: 100 patients were randomized, 49 to the treatment with atorvastatin and 51 to placebo. Patients in the
atorvastatin group had a significantly lower conversion rate to severe sepsis compared to placebo (4% vs. 24% p =
0.007.), with a number needed to treat of 5. No significant difference in length of hospital stay, critical care unit
admissions, 28-day and 12-month readmissions or mortality was observed. Plasma cholesterol and albumin
creatinine ratios were significantly lower at day 4 in the atorvastatin group (p < 0.0001 and p = 0.049 respectively).
No difference in adverse events between the two groups was observed (p = 0.238).
Conclusions: Acute administration of atorvastatin in patients with sepsis may prevent sepsis progression. Further
multi-centre trials are required to verify these findings.
Trial Registration: International Standard Randomized Control Trial Registry ISRCTN64637517.
Introduction
Sepsis describes a complex clinical syndrome that results
from a harmful or damaging host response to infection.
It is commonly seen in hospital emergency departments
and wards with an estimated prevalence of 15% in the
UK. A significant proportion of patients with sepsis go
on to develop severe sepsis or septic shock with asso-
ciated mortality rates of up to 50% [1,2]. Despite consid-
erable research there still remains a lack of targeted
pharmacological interventions to treat and improve out-
comes from sepsis.
Statins inhibit 3-hydroxy-3 methylglutaryl coenzyme A
(HMG-CoA) reductase, a rate-limiting enzyme in the
biosynthesis of cholesterol. They are well established in
the prevention of cardiovascular disease and have been
shown to exert numerous effects in addition to their
lipid-lowering properties. These pleiotropic properties
include anti-inflammatory and immunomodulatory
effects resulting in improved endothelial function,
reduced thrombogenicity and plaque stabilisation [3-5].
The inflammatory and immune response provoked by
sepsis could potentially be modulated by statins via
these pleiotropic effects. Several systematic reviews have
concluded that statins have a role in improving infec-
tion-related outcomes and mortality but most of this
evidence comes from retrospective and prospective
observational studies [6,7]. In a prospective cohort study
of 361 patients it was reported that patients already
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receiving statin therapy had reduced rates of severe sep-
sis and intensive care admissions [8]. So far there have
been only two published randomized controlled trials
(RCTs) investigating the role of statins in sepsis. One of
these, a double-blind RCT to assess whether acute
administration of statins reduced sepsis progression and
cytokine production was stopped prematurely due to
slow recruitment and was unable to analyse data relating
to sepsis conversion. There were significantly decreased
levels of IL-6 and TNF-a at 72 hours, however, com-
pared with baseline (P = 0.02) [9]. A more recent RCT
investigated whether continuation of pre-existing statin
therapy prevented conversion of sepsis to severe sepsis.
It concluded that continuation of statin therapy did not
reduce progression of sepsis or the development of
organ failure and that the witholding of statin therapy
did not result in any inflammatory rebound [10].
The recent withdrawal from the market of recombinant
activated protein C (drotrecoginalfa, rhAPC) following the
results of the PROWESS-Shock trial has resulted in there
being no specific therapy for sepsis other than source con-
trol and antibiotics [11,12]. Statins offer a safe multi-
modal mechanism to target the inflammatory and immu-
nological cascade of sepsis which could be prescribed to
patients prior to the establishment of septic shock.
The aim of this study was to evaluate whether the acute
use of atorvastatin 40 mg/day in ward patients with sepsis
would significantly reduce rates of conversion of sepsis to
severe sepsis (≥ one organ failure) compared with placebo
in patients not previously treated with statins.
Materials and methods
Study design
This was a single centre randomized, double-blind, par-
allel, placebo-controlled clinical trial. Ethical approval
was granted by the South Birmingham Research Ethics
Committee and the trial was registered with the Interna-
tional Standard Randomized Control Trial Registry
(ISRCTN64637517). Valid informed written consent was
obtained from all patients or their next of kin prior to
enrolment in the trial.
Study participants
Between June 2006 and August 2008, patients admitted
to Birmingham Heartlands Hospital within 24 hours,
with a white cell count (WCC) > 11 or < 4 × 109/L and
with C-reactive protein (CRP) 2 SD above the upper limit
of normal (6 mg/L), were identified from the hospital’s
iCARE Vortal database. These patients were screened
further for eligibility for enrolment into the trial.
The inclusion criteria [13] were as follows: age greater
than 18 years; documented new proven or suspected infec-
tion, and the presence of any two of the signs and symp-
toms of infection (WCC > 11 or < 4 × 109/L, temperature
> 38°C or < 36°C, heart rate > 90/bpm, or respiratory rate
> 20/minute) for less than 24 hours. We excluded patients
with evidence of severe sepsis defined by the Surviving
Sepsis Campaign Guideline (SSCG), that is, sepsis with
failure of one or more organs [14]; pregnancy; acute or
chronic liver failure; evidence of myopathy; rhabdomyoly-
sis, or terminal illness. Prior statin therapy within 2 weeks,
the concomitant use of macrolides, imidazoles, or other
lipid-lowering therapy, and the inability to swallow also
precluded enrollment.
An amendment was approved to allow enrolment of
patients prescribed macrolides. These antibiotics form
part of local guidelines for treatment of community-
acquired pneumonia and are frequently prescribed. The
additional risk of myopathy caused by competition for
metabolism by cytochrome P450 3A4 between atorvastatin
and macrolides was deemed to be mitigated by the careful
monitoring of serum creatinine kinase (CK).
Randomization and blinding
Study drug packs were prepared by DHP pharma (Powys,
UK). The active and placebo drug components of capsules
were packaged identically into numbered treatment packs,
each containing 40 mg atorvastatin (Pfizer, Sandwich, UK)
or placebo. We used a computer-generated randomization
sequence with a block size of four. Patients were randomly
assigned in a 1:1 ratio by a centralised randomization
service (Heartlands Hospital Pharmacy, England, UK).
Participants, care providers, and investigators were blinded
to group assignment. Study drug was administered orally
within 24 hours of randomization. Treatment continued
for the duration of their hospital stay or 28 days if earlier.
All other therapeutic decisions were at the discretion of
the primary physician.
Data collection
We obtained the data for diagnosis of sepsis and severe
sepsis from medical notes and laboratory reports. Data
was also collected to calculate Acute Physiology and
Chronic Health Evaluation II (APACHE II) scores with its
predicted hospital mortality and Modified Early Warning
Scores (MEWS) to evaluate the severity of patients’ condi-
tions at baseline. We followed all participants up to 12
months after randomization and collected data for critical
care admission rate, hospital readmissions at 28 days and
1 year, length of hospital stay, and 28-day and 1-year mor-
tality. Quality of life (QOL) data were collected at baseline
and day of discharge using the validated EuroQol visual
analogue scale (see Additional file 1).
Laboratory investigations
Appropriate microbiological samples were sent for cul-
ture to establish the site of infection and pathogen and
collection was guided by clinical condition. Full blood
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count, plasma urea and electrolytes, liver function tests,
CK levels, coagulation studies and arterial blood gas ana-
lysis were recorded. Lipid profiles and CRP were mea-
sured at baseline, day 4, day 7 and day 28. Urine samples
were collected at the same intervals to measure urine
albumin creatinine ratios (ACR).
Study outcomes
The primary outcome was the progression rate of sepsis to
severe sepsis during the hospital stay or by 28 days if ear-
lier. The progression of sepsis to severe sepsis was identi-
fied using the SSCG screening tool as described in Table 1
(see Additional file 2). Secondary outcomes were critical
care unit (CCU) admission rate, hospital readmission rate
at 28 days and 1 year, length of hospital stay, and hospital
28-day and 1-year mortality.
Sample size and statistical analysis
Based on limited data available at the time [8], it was pos-
tulated that statins might reduce the absolute rate with
which sepsis converted to severe sepsis by 15% (40% to
25% change). To detect such a reduction in risk, with a
power of 80% and at the 5% level of significance, a total of
414 patients (n = 207 in each group) would be required.
Based on the local and very limited European epidemiolo-
gical data available at the time, it was expected that the
trial would need 30 months for recruitment and 12 month
for post-randomisation follow-up, making the total dura-
tion 42 months (3.5 years).
Data were analysed by an independent statistician on an
intention-to-treat basis using SPSS for Windows 7. Data
were tested for normality and analysed by unpaired t-tests
or Mann Whitney U-test. Data are expressed as mean
(SD) or median (interquartile range, IQR) as appropriate.
The chi squared or Fisher’s exact test was used to compare
proportions. A P-value of 0.05 was considered significant.
Results
The screening for inclusion criteria was started in June
2006 and ended in August 2008 due to slow recruitment.
During this period a total of 2,150 patients were screened;
1,292 (60%) of these were diagnosed with sepsis according
to SSCG, and 433 (34%) met the inclusion criteria with
100 patients consenting to randomization (49 randomized
to atorvastatin and 51 to placebo). No patients were lost
to follow-up during their admission and all patient data
were included in the analysis. Figure 1 shows the trial
profile.
Patients in the two groups were well-matched in terms
of the demographic data, biochemical presentations, global
severity of illness (APACHE II and MEWS scores) and
sources of sepsis (Table 2). Seven patients in the atorvasta-
tin and thirteen in the placebo group had confirmed posi-
tive microbiology samples that isolated the sources of
sepsis, (P = 0.21). Both groups received appropriate anti-
microbial therapy (77% vs. 82%, P = 0.65) and received a
similar number of trial drug doses (three vs. five, P = 0.32).
Primary outcome
The atorvastatin group had a significantly lower incidence
of sepsis converting to severe sepsis (n = 2 patients) com-
pared to the placebo group (n = 12) (4% vs. 24%, P =
0.007, number needed to treat = 5). Patients progressing
to severe sepsis predominantly had respiratory failure (n =
7) with one patient requiring mechanical ventilation and
one requiring inotropic support. Three patients in the pla-
cebo group developed failure of more than one organ,
compared with one patient in the atorvastatin group
(Table 3).
Secondary outcomes
The 28-day mortality was 4% with two deaths in each
group (P = 1.0), while 1-year mortality was 8% (four
patients in the atorvastatin group vs. four in the placebo
group, P = 1.0), making overall mortality for the cohort
12% (Table 4). Median length of hospital stay for the ator-
vastatin and placebo groups was five days (IQR 3 to 13)
and six days (IQR 4 to 12) respectively (P = 0.59). There
was no effect on rates of CCU admission between the
groups (n = 0 vs. 2 patients, P = 0.495). Of the 96 survi-
vors, 28-day readmission data were available for 89
(92.7%). There were ten sepsis-related readmissions, with
five in each group (P = 1.0). At 1 year 89 (89%) patients
had survived and readmission data were available for 88
Table 1 Criteria used for classifying organ dysfunction and progression to severe sepsis
Severe sepsis defined as new or suspected infection with one or more organ dysfunctions Organ dysfunction defined as:
Cardiovascular SBP < 90, MAP < 65 mmHg or > 40 mmHg fall in SBP from baseline and/or use of noradrenaline/dobutamine/dopamine
Respiratory Bilateral pulmonary inflitrates with new or increased oxygen requirements to maintain oxygen saturations > 90% or bilateral
pulmonary inflitrates with a PaO2/FiO2 ratio < 300 mmHg
Renal Creatinine > 176.8 mmol/L or urine output < 0.5 mls/kg/hr for > 2 hrs
Haematological Platelets < 100,000/mm3
INR > 1.5 or APTT > 60 secs
Liver/metabolic Bilirubin > 34.2 mmol/L
Lactate > 2 mmol/L
APTT: activated partial thromboplastin time; INR; international normalized ratio; MAP: mean arterial pressure; SBP: systolic blood pressure.
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(98.9%) with no significant difference between the groups
for the number of readmissions (P = 0.541).
QOL data assessed by the EuroQol visual analogue
scale showed a significant increase in mean score from
baseline to discharge for the cohort (45.2 vs. 65.4, 95%
confidence interval (CI) 37.0, 72.3, P < 0.0001)
representing a perceived improvement in QOL. No dif-
ference was observed between the two groups in median
score at baseline (50.0 vs. 40.0, IQR 20 to 60, P = 0.51).
At discharge, however, the placebo group had a better
perceived median QOL score than the atorvastatin
group (60.0 vs. 77.5, IQR 51.3 to 78.8, P = 0.02).
Figure 1 Consort diagram illustrating the screening, enrolment and randomization of study patients.
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The change from baseline in lipid profiles for the two
groups is shown in Table 5. No differences in baseline
plasma cholesterol, high-density lipoprotein (HDL), low
density lipoprotein (LDL) or triglycerides were observed
between the groups. At day 4 a significant decrease was
observed in plasma cholesterol and LDL (P < 0.0001
and 0.019 respectively) in the atorvastatin group com-
pared to placebo. No difference in HDL or triglycerides
was seen (P = 0.442 and 0.210 respectively).
No difference in ACR was observed between the
groups at day 1 or day 4. A significant reduction in albu-
min excretion in the atorvastatin group was seen between
days 1 and 4 compared to placebo (p = 0.049 vs. 0.796,
Figure 2).
Adverse events
Serial blood samples were taken to monitor any serious
adverse events due to statin therapy. There were no
cases of raised transaminase levels in either group.
There were, however, two patients with raised CK above
1,400 U/L in the atorvastatin group (P = 0.238). Both
patients were diagnosed with acute coronary syndrome
and the CK rise was attributed to this. There were no
episodes of myalgia.
Discussion
To our knowledge, this randomized control trial is the
first to investigate the impact of the acute administra-
tion of statins on progression of sepsis in statin-naïve
individuals. It demonstrates that statins were well
absorbed in patients with sepsis, and administration
early in the septic process significantly reduced the like-
lihood of sepsis progressing to severe sepsis. One case
Table 2 Patients’ baseline demographics and biochemical data
Atorvastatin
n = 49
Placebo
n = 51
P-value
Age, years, mean (SD) 62.8 (21.2) 64 (15.6) 0.745
Male gender, % 51 51 0.570
Scoring systems
MEWS, mean (SD) 2.8 (2.1) 3.3 (2.1) 0.197
APACHE II, mean (SD) 11.8 (5.6) 11.9 (6.0) 0.914
Predicted mortality, median (IQR) 14.6 (8.7, 23.5) 12.9 (7.6, 26.2) 0.909
Biochemical data
Cholesterol, mmol/L, median (IQR) 4.0 (2.9, 5.1) 4.35 (3.35, 5.35) 0.505
Neutrophils, × 109/L median (IQR) 11.6 (8.3, 13.7) 12.4 (9.3, 19.4) 0.232
C-reactive protein, mg/L, mean (SD) 194.6 (114.6) 188.0 (127.3) 0.683
Source of infection, number of cases
Pneumonia 27 24 0.674
Urinary tract 8 9 0.808
Cellulitis 6 10 0.317
Gastrointestinal 5 7 0.563
Bacteraemia 2 1 0.563
Urinary catheter 1 0 0.317
Antibiotic therapy, number of patients 38 42 0.654
Co-morbidities, number of patients
0 15 17 0.832
1 22 21 0.840
2 7 6 0.772
3 or more 5 8 0.554
Number of trial drug doses, median (IQR) 3 (2, 7) 5 (2, 8) 0.322
MEWS, modified early warning score; APACHE, acute physiology and chronic health evaluation; IQR, interquartile range.
Table 3 Organ failure in the atorvastatin and placebo
groups
Atorvastatin Placebo
Respiratory failure without mechanical
ventilation
0 7
Respiratory failure with mechanical ventilation 0 1
Cardiovascular failure without inotropes 1 0
Cardiovascular failure with inotropes 0 1
Renal failure without RRT 0 0
Neurological 0 0
Failure of more than one organ 1 3
Totals 2 12
Results are presented as number of patients. RRT: renal replacement therapy.
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of severe sepsis was prevented for every five patients
with sepsis.
This randomized controlled trial supports previous
retrospective and prospective observational studies
demonstrating that patients who are on pre-existing sta-
tin therapy have better sepsis-related outcomes com-
pared to matched controls [4,6,8].
The significant reduction in urinary ACR at day 4 in
the statin-treated group may explain slowing of sepsis
progression in that group. Albumin excretion in urine is
tightly regulated by the kidneys. In inflammatory states,
especially sepsis, however, glomerular permeability
increases due to altered endothelial function, resulting in
increased protein excretion. This is an early sign in sepsis
and persists in patients who develop organ dysfunction.
We postulate that the significant reduction seen in ACR
in the statin group may reflect less damage in endothelial
function and hence a reduction in the progression of sep-
sis [15,16].
The atorvastatin group showed significant decreases in
both plasma cholesterol and LDL between days 1 and 4.
This demonstrates compliance with treatment, absorption
of statins and effective plasma concentrations being
achieved to cause decreases in plasma lipids. The ability of
atorvastatin to reduce lipid levels after only three doses in
combination with the reduced rates of sepsis progression
seen would indicate that statins are able to exert their
pleiotrophic effects acutely, thereby modulating the
immune and cellular responses to sepsis. The HARP study
showed that 80 mg of simvastatin administered acutely to
patients with acute lung injury showed significant
improvements in organ failure scores, suggesting that sta-
tins modulate the systemic inflammation after only a short
duration of treatment [17].
EuroQol scores at baseline were low for the cohort indi-
cating that the majority of patients considered their QOL
to have deteriorated substantially from health due to their
sepsis-related hospital admission. This is not surprising;
however, when compared to their physiological and biolo-
gical markers of infection, such as APACHE II scores,
which were low, the EuroQOL scores indicate that
although our patients had relatively mild disease they per-
ceived their illness to have had a significant impact on
their QOL. Reassuringly, the EuroQol scores had
improved significantly by the time of discharge, suggesting
that patients had improved not only in terms of bio-physi-
cal markers of disease but also in their personal well-being.
Although the trial did not achieve its recruitment target,
it is still the second largest RCT to date investigating the
role of statins in sepsis, and is the first to suggest benefit
from acute statin therapy. The screening process involved
assessing all admissions to the hospital on the basis of
laboratory levels of CRP, WCC and systemic inflammatory
response syndrome (SIRS) criteria. This process was
neither specific nor sensitive for identifying patients with
sepsis, and a high refusal rate was seen among those who
were subsequently eligible for randomization. The major-
ity of patients randomized were not critically ill, as
Table 4 Length of stay, readmission and mortality data
Atorvastatin
n = 49
Placebo
n = 51
P-value
Length of hospital stay, median (interquartile range) 5 (3, 13) 6 (4, 12) 0.598
Readmissions, number
Within 28 days 5 5 1.0
(n = 43) (n = 46)
Within 1 year 7 5 0.541
(n = 42) (n = 45)
Mortality, number of patients
28 days 2 2 1.0
1 year 4 4 1.0
Table 5 Median lipid profiles in the placebo and atorvastatin groups at day 4 of follow-up compared to baseline
Placebo
Difference from day 1
n = 31/31*
Atorvastatin
Difference from day 1
n = 23/25*
Comparison
atorvastatin-placebo
P-value
Total cholesterol (mmol/L) 0.30 -0.50 -0.8 (-0.9, -0.8) < 0.0001
LDL(mmol/L) 0.16 -0.63 -0.79 (-0.93, -0.47) 0.019
HDL (mmol/L) -0.18 -0.40 -0.22 (-0.53, 0.01) 0.227
Triglycerides (mmol/L) 0.50 0.20 -0.30 (-1.0, 0.40) 0.79
*Number of samples available for analysis. Denominator represents number of patients still in hospital at day 4. Values represent median and IQR. LDL, low
density lipoprotein; HDL, high density lipoprotein.
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observed by their low APACHE II scores at baseline. This
supports previous studies that have encountered similar
recruitment problems when conducting sepsis-related
research on ward-based patients, as the vast majority are
not critically ill at admission, have a low rate of progres-
sion of sepsis, and the diagnosis of sepsis remains non-
specific and non-sensitive [9,10]. Recent validation studies
using the predisposition, insult, response, organ dysfunc-
tion (PIRO) model for stratification of risk of sepsis have
suggested that this may allow more sensitive and specific
phenotyping of patients with sepsis. Future studies into
sepsis should consider using such models as opposed to
the classical criteria used in this study to increase the like-
lihood of targeting desired populations [18].
Conclusions
In conclusion, our study is the first RCT to demonstrate a
benefit from acute administration of atorvastatin 40 mg
daily for preventing the progression of sepsis in statin-
naïve individuals. We postulate that statins may modulate
the pathophysiology of sepsis via a novel cellular mechan-
ism thereby restoring endothelial integrity and thus block-
ing one of the mechanisms in the development of multi-
organ failure. Future large-scale multi-centre RCTs are
required to investigate whether these results are reprodu-
cible, further explore the role of statins in sepsis and eluci-
date the cellular mechanisms by which statins confer
protection in sepsis.
Key messages
• Atorvastatin 40 mg per day may prevent the pro-
gression of sepsis to severe sepsis in hospitalized
patients.
• Statins may act acutely to prevent organ dysfunction.
• Cellular mechanisms of organ protection need
further evaluation, which may be associated with the
improvement of endothelial integrity.
• Larger RCTs are warranted to establish whether
statins can to be used in the early phases of sepsis to
prevent the onset of organ failure.
Additional material
Additional file 1: EUROQOL II Score. This was the visual analogue
score part of the EUROQOL II score that was used to assess quality of
life.
Additional file 2: Surviving Sepsis Campaign Screening Tool. This
was the validated screening tool used to identify patients with sepsis
and those that progressed to severe sepsis.
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